Hilal Karakaş

Dr. Hilal Karakaş


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SESafa Can Efil
Safa Can Efil
FKFatih Kuş
Fatih Kuş
BKBahadır Köylü
Bahadır Köylü
BDBekir Mert Durukan
Bekir Mert Durukan
SBSelami Bayram
Selami Bayram
MSMehmet Ali Nahit SENDUR
Mehmet Ali Nahit SENDUR
Background: Durvalumab combined with gemcitabine–cisplatin (GC) has become the standard first-line treatment for advanced biliary tract cancer (BTC) following the TOPAZ-1 trial. However, real-world effectiveness, safety, and prognostic determinants, particularly in underrepresented populations, remain insufficiently defined. The aim of this study was to evaluate the real-world outcomes of first-line durvalumab plus chemotherapy and identify independent prognostic factors in patients with advanced BTC. Methods: This multicenter retrospective cohort study included patients with unresectable or metastatic BTC treated with first-line durvalumab plus chemotherapy across 21 tertiary oncology centers in Türkiye. Clinical characteristics, laboratory parameters, biomarker data, and treatment details were collected. The primary endpoint was overall survival (OS), while secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. Survival outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards regression models. Results: A total of 78 patients were analyzed; 53.8% were male, and the median age was 62 years. Primary tumor sites were intrahepatic (55.1%), extrahepatic (30.8%), and gallbladder (14.1%). After a median follow-up of 12.58 months, median OS was 11.59 months and median PFS was 6.80 months. The ORR was 50.6%, including complete and partial responses in 2.7% and 47.9% of patients, respectively. Treatment-related adverse events occurred in 97.4% of patients, with grade 3–4 events in 37.2%. Immune-related adverse events were observed in 19.2%, including one case of grade 3 pneumonitis. No patient permanently discontinued durvalumab due to toxicity, and no durvalumab-related mortality occurred. In multivariable analysis, ECOG performance status 2 (HR 3.43; 95% CI 1.33–8.80) and ALBI grade 2–3 (HR 2.54; 95% CI 1.24–5.19) independently predicted worse OS, while ECOG performance status 2 also predicted shorter PFS (HR 5.91; 95% CI 2.30–15.17). Conclusions: In this multicenter real-world Turkish cohort, first-line durvalumab plus chemotherapy showed effectiveness and tolerability comparable to clinical trial data. Baseline ECOG performance status and ALBI grade were independent prognostic factors, supporting their use for risk stratification in advanced biliary tract cancer.

3 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PPPerihan Perkin
Perihan Perkin
DSderya sarıkaya
derya sarıkaya
HKHilal Karakaş
Hilal Karakaş
UÖUĞUR ÖZBERK
UĞUR ÖZBERK
BBBurak Bilgin
Burak Bilgin
GUGokhan Ucar
Gokhan Ucar
Background/Objectives: The optimal adjuvant chemotherapy regimen remains uncertain for some patients with hormone receptor (HR)-positive/HER2-negative early breast cancer, particularly regarding the incremental benefit of anthracyclines. We compared real-world outcomes with docetaxel-plus-cyclophosphamide (TC) and anthracycline–taxane chemotherapy. Methods: This retrospective single-center cohort included patients with stage I–III HR-positive/HER2-negative breast cancer who underwent surgery and received adjuvant TC or anthracycline–taxane chemotherapy between 2019 and 2025. Patients receiving neoadjuvant systemic therapy were excluded. Disease-free survival (DFS) was the primary outcome and overall survival (OS) the secondary outcome. Propensity score overlap weighting adjusted for measured baseline differences was used; the absolute difference in weighted 3-year DFS was the primary adjusted measure. Results: Among 361 patients, 201 received TC and 160 anthracycline–taxane chemotherapy. The anthracycline–taxane group had higher baseline clinicopathologic risk. Median follow-up was 39.0 months. Twelve DFS events occurred (TC, n = 3; anthracycline–taxane, n = 9). Unadjusted 3-year DFS was 99.0% versus 96.6% (p = 0.096), and 3-year OS was 99.4% versus 99.1% (p = 0.725). The overlap-weighted analysis included 346 patients and achieved adequate covariate balance. Weighted 3-year DFS was 99.2% with TC and 96.5% with anthracycline–taxane chemotherapy, an absolute difference of 2.68 percentage points (95% CI, −1.81 to 10.03). Sensitivity analysis yielded similar results (2.70 percentage points; 95% CI, −1.76 to 9.87). Conclusions: No statistically significant difference in 3-year DFS was demonstrated after adjustment. Limited events and relatively short follow-up preclude conclusions regarding equivalence or noninferiority. These findings support individualized adjuvant chemotherapy selection and warrant confirmation in larger cohorts with longer follow-up.

15 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
HKHilal Karakaş
Hilal Karakaş
SESafa Can Efil
Safa Can Efil
BBBurak Bilgin
Burak Bilgin
YEYakup Ergun
Yakup Ergun
MBMurat Bardakçı
Murat Bardakçı
MŞMehmet Ali Nahit Şendur
Mehmet Ali Nahit Şendur
Background: Reliable biomarkers to predict response to immune checkpoint inhibitors (ICIs) in non–small cell lung cancer (NSCLC) remains limited.ABO blood group antigens may influence tumor immunity and response to immunotherapy. Methods: We retrospectively analyzed patients with advanced NSCLC treated with ICIs between 2019 and 2024. Patients were classified according to ABO blood group. Overall survival (OS), progression-free survival (PFS), and treatment response were evaluated. Results: Patients with blood group O demonstrated significantly longer OS (18.6 vs 11.0 months, p< 0.001) and PFS (9.4 vs 4.2 months, p=0.001). Conclusion: ABO blood group, particularly blood group O, may serve as a clinically relevant host-related prognostic biomarker in NSCLC immunotherapy.